vomiting, pain management and other central nervous system disorders.
-- Nanosphere, which develops, manufactures and markets an advanced
molecular diagnostics platform, the Verigene system, that enables
highly sensitive genomic and protein testing on a single platform.
-- Precision Therapeutics, which develops and commercializes tests
intended to assist physicians in individualizing cancer therapy in an
effort to improve treatment outcomes, filed.
"It promises to be an interesting next few months," said Burrill, "while the industry is still remains at the mercy of the macro-economic climate, the stage is set for biotech to build value and finish the year with a flourish."
AUGUST INDICES
Index 7/31/02 12/29/06 7/31/07 8/31/07 %change %change %change
Month Year 5-Year
Burrill
Biotech Select 184.23 303.96 319.81 334.03 4.45% 9.40% 81.31%
Burrill
Large Cap 194.4 424.56 410.71 422.76 2.93% -0.44% 117.47%
Burrill
Mid-Cap 133.51 171.55 187.88 190.01 1.13% 9.83% 42.32%
Burrill
Small Cap 85.13 143.6 130.12 135.05 3.79% -6.57% 58.64%
Burrill
Genomics 106.25 101.69 86.85 88.9 2.36% -14.73% -16.33%
Burrill IPO N/A 63.33 46.92 50.43 7.48% -27.49% N/A
Burrill AgBio 67.22 124.52 161.38 164.79 2.11% 24.95% 145.15%
Burrill
Industrial N/A 150.85 160.53 159.54 -0.62% 5.41% N/A
Burrill
Diagnostic 65.86 122.79 153.09 162.55 6.18% 25.97% 146.81%
Burrill
Nutraceutical 113.12 629.56 597.97 611.27 2.22% -3.06% 440.37%
NASDAQ 1328.3 2415.29 2546.27 2596.36 1.97% 7.11% 95.46
'/>"/>
| SOURCE Burrill & Company Copyright©2007 PR Newswire. All rights reserved |